ArticleDigital health
Investigating the barriers to uptake and utilization of overdose response hotlines and apps: A study based on data from a national survey.
Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Overdose Response Hotlines and Apps (ORHAs) are novel technologies designed to avert fatal overdose associated with solitary use of illicit substances. While they can be a useful tool for those who cannot reach in-person harm reduction support, previous literature has cited potential barriers to their access. The aim of this study was to quantitatively evaluate the types of barriers that may hinder the uptake and utilization of ORHAs from the perspective of key stakeholders. Methods: The current study reports on the data obtained from Canadian National Questionnaire on Overdose Monitoring (CNQOM) focusing on people who currently use substances (PWUS-C), have used substances in the past (PWUS-P), and addiction service providers (ASP). A combination of purposive and representative sampling was used for recruitment. A list of potential partner organizations across Canada was contacted between July 2022 and May 2023. We explored logistical, technological, and social barriers to assess the acceptability of ORHAs. Results: A total of 971 participants were included in this study, consisting of 268 PWUS-C, 525 PWUS-P, and 178 ASP. Barriers to ORHA were categorized into: service delivery and quality barriers, technological barriers, and stigma/social barriers. More than half of the respondents across all groups rated the barriers as 4 (significant) or higher on the Likert scale. Ordinal logistic regression revealed that being an ASP was associated with higher likelihood of rating certain barriers as more significant compared to PWUS-C and PWUS-P. Conclusion: This study is the first to quantify concerns about potential barriers to the use of ORHAs from the perspectives of key Canadian interest groups and provide valuable information on how to improve accessibility and utility of overdose prevention technologies to a wider range of demographics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.